Altimmune launches trial of t-covidtm for patients with early covid-19

Altimmune launches clinical trial of t-covidtm, an investigational intranasal immune modulator for the treatment of patients with early covid-19.altimmune inc - planned phase 1/2 outpatient clinical trial will focus on patients with early sars-cov-2 infection.altimmune inc - placebo-controlled trial expected to commence in june with data readout expected in q4 2020.
ALT Ratings Summary
ALT Quant Ranking